This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

Litigation Settlements, Data Compliance Reviews, And Clinical Trials Pave Way For Solid Footing In Healthcare - Research Report On Pfizer, Merck, Bristol-Myers Squibb, Keryx And Pacira Pharmaceuticals

Stocks in this article: BMYKERXMRKPCRXPFE

Bristol-Myers Squibb Company Research Report

On June 12, 2013, Bristol-Myers Squibb Company (Bristol Myers Squibb) and AstraZeneca announced that they will continue to work with health authorities and scientific experts around the world to closely monitor the use of our GLP-1 receptor agonist and DPP-4 inhibitor through comprehensive surveillance programs to ensure patients and physicians have a clear understanding of the risk/benefit profile of these medications. This announcement came after the American Diabetes Association (ADA) called for incretin-based therapies manufacturers to make available the patient-level data from clinical trials for an independent analysis of pancreatic safety. The Full Research Report on Bristol-Myers Squibb Company - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [ http://www.WSReports.com/r/full_research_report/88a2_BMY]

--

Keryx Biopharmaceuticals Inc. Research Report

On June 3, 2013, Keryx Biopharmaceuticals, Inc. (Keryx) announced the presentation of updated efficacy and safety data from the Phase 3 long-term clinical trial of ZenerexZerenex (ferric citrate). Based on the efficacy results, Keryx determined that Zerenex is an efficacious and safe oral phosphate binder that controls serum phosphorus, increases iron stores as measured by serum ferritin and TSAT, and reduced the use of IV iron and ESAs, while sustaining hemoglobin as compared to the active control group. ZenerexZerenex met the pre-defined primary and key secondary endpoints for the treatment of elevated serum phosphorus levels, or hyperphosphatemia, in patients with end-stage renal disease (ESRD) on dialysis. The Full Research Report on Keryx Biopharmaceuticals Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [ http://www.WSReports.com/r/full_research_report/27d7_KERX]

--

Pacira Pharmaceuticals ,  Inc. Research Report

On May 29, 2013, Pacira Pharmaceuticals, Inc. (Pacira) announced the findings from the completed first part of its Phase 2/3 clinical trial for the assessment of the use and administration of Exparel (bupivacaine liposome injectable suspension) as a single-dose injection femoral nerve block for total knee arthroplasty surgery (TKA). Dave Stack, President and CEO of Pacira, stated, "We are pleased with the interim analysis of the safety and efficacy of EXPAREL in this important orthopedic indication." Stack continued, "Based on the independent Data Safety Monitoring Board analysis, we believe that a single-dose injection of EXPAREL as a femoral nerve block can provide several days of analgesia without significant motor blockade. We look forward to initiating the Phase 3 portion of this trial and ultimately to providing orthopedic patients with a new option that could significantly contribute to the management of their postsurgical pain by replacing a perineural catheter, drug reservoir and pump with a single-dose injection of EXPAREL." The Full Research Report on Pacira Pharmaceuticals, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [ http://www.WSReports.com/r/full_research_report/c8a5_PCRX]

----

2 of 4

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 16,614.81 +215.14 1.31%
S&P 500 1,941.28 +37.27 1.96%
NASDAQ 4,419.4780 +103.4040 2.40%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs